Evotec and GV have invested in Carrick Therapeutics, a company commercialising research from institutions including Cambridge and Oxford universities and Imperial College London.

Ireland-based cancer-focused biotechnology company Carrick Therapeutics raised $95m today from a consortium including GV, the corporate venturing arm of conglomerate Alphabet, and drug discovery company Evotec. The round was co-led by Arch Venture Partners, the VC firm spun out of Chicago University’s tech transfer office, and investment firm Woodford Investment Management. It further featured Cambridge…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.